As COVID-19 patients swamp intensive care units, Health Canada is reviewing the experimental pill molnupiravir, which claims to reduce the disease's worst outcomes early on.
According to drugmaker Merck, the twice a day antiviral pill reduced hospitalizations and deaths in COVID-19 patients by 50 per cent based on clinical trials. But the drug is not approved yet and still needs more review.
Jamie Mauracher looks at what we know and don't know about the drug, and how it may help ease the health system's burden.
For more info, please go to https://globalnews.ca/news/8235523/experimental-pill-fights-covid-19-merck/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews
According to drugmaker Merck, the twice a day antiviral pill reduced hospitalizations and deaths in COVID-19 patients by 50 per cent based on clinical trials. But the drug is not approved yet and still needs more review.
Jamie Mauracher looks at what we know and don't know about the drug, and how it may help ease the health system's burden.
For more info, please go to https://globalnews.ca/news/8235523/experimental-pill-fights-covid-19-merck/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews
- Category
- U.S. & Canada
- Tags
- global news, COVID-19 pill, Merck
Sign in or sign up to post comments.
Be the first to comment